Role of FDG-PET/CT in Assessing the Correlation Between Blood Pressure and Myocardial Metabolic Uptake

Document Type: Original Article


1 Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States

2 Department of Radiology, Children’s Hospital of Philadelphia, Philadelphia, United States

3 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark


Objective(s): We aimed to assess the association between blood pressure and LV myocardial uptake of FDG, hypothesizing that subjects with raised blood pressure would have higher FDG uptake.
Methods: We analyzed 86 healthy controls who underwent PET/CT imaging 180 minutes following FDG (4 MBq/Kg) administration. LV myocardial analysis was performed on axial sections using standard operator guided computer software (OsiriX MD). The average LV myocardial SUVmean (MSUVmean) was calculated for each subject. Subjects were assessed according to the 2017 ACC/AHA guidelines for high blood pressure in adults. Mean arterial blood pressure (MABP) was calculated for each patient. Regression models were employed for statistical analysis. 
Results: The association of MSUVmean was more pronounced with DP (r=0.32, p=0.003) than SP (r=0.28, p=0.010); MABP was comparable (r=0.33, p=0.002). Correlations of MSUVmean with categorized BPs were: normal SP (r=0.27, p=0.010), elevated SP (r=0.28, p=0.009), stage 1 SP (r=0.27, p=0.010), stage 2 SP (r=0.28, p=0.008); normal DP (r=0.33, p=0.001), stage 1 DP (r=0.34, p=0.001), stage 2 DP (r=0.35, p=0.001). Multivariate analysis demonstrated DP (p=0.006), MABP (p=0.007), and SP (0.026).
Conclusion: LV myocardial FDG uptake was higher in subjects with elevated blood pressure and correlated positively with SBP and in particular DBP and MABP.


Main Subjects

1. Members WG, Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017; 135(10):e146.

2. Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Current hypertension reports. 2013; 15(3):134-6.

3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. The lancet. 2005; 365(9455):217-23.

4. Fry J. Deaths and complications from hypertension. JR Coll Gen Pract. 1975; 25(156):489-94.

5. Mehta NN, Torigian DA, Gelfand JM, Saboury B, Alavi A. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). Journal of visualized experiments: JoVE. 2012(63).

6. Seraj SM, Pournazari K, Ayubcha C, Jahangiri P, Khosravi M, Werner T, et al. Global assessment of joints in patients with rheumatoid arthritis: Quantification of inflammatory lesions in FDG-PET. Journal of Nuclear Medicine. 2018; 59(supplement 1):1208-.

7. Shivamurthy VK, Tahari AK, Marcus C, Subramaniam RM. Brain FDG PET and the diagnosis of dementia. American Journal of Roentgenology. 2015; 204(1):W76-W85.

8. Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. Cancers. 2014; 6(4):1821-89.

9. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA /ASH /ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018; 71(19):e127-e248.

10. Harrell Jr FE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis: Springer; 2015.

11. Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. The lancet. 1986; 327(8476):307-10.

12. Bland JM, Altman DG. Measuring agreement in method comparison studies. Statistical methods in medical research. 1999; 8(2):135-60.

13. Kottner J, Audigé L, Brorson S, Donner A, Gajewski BJ, Hróbjartsson A, et al. Guidelines for reporting reliability and agreement studies(GRRAS) were proposed. International journal of nursing studies. 2011; 48(6):661-71.

14. Lo S, Li I, Tsou T, See L. Non-significant in univariate but significant in multivariate analysis: a discussion with examples. Changgeng Yi Xue Za Zhi. 1995; 18(2):95-101.

15. Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart. 2005; 91(2):250-6.

16. Aoyama R, Takano H, Kobayashi Y, Kitamura M, Asai K, Amano Y, et al. Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography. PloS one. 2017; 12 (11):e0188479.

17. Bishop SP, Altschuld RA. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. American Journal of Physiology-Legacy Content. 1970; 218(1):153-9.

18. Shao D, Tian R. Glucose transporters in cardiac metabolism and hypertrophy. Comprehensive Physiology. 2011; 6(1):331-51.

19. Takeishi Y, Masuda A, Kubo H, Tominaga H, Oriuchi N, Takenoshita S. Cardiac imaging with 18F-fluorodeoxyglucose PET/MRI in hypertrophic cardiomyopathy. Journal of Nuclear Cardiology. 2017; 24(5):1827-8.

20. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiological reviews. 2005; 85(3):1093-129.

21. Kolwicz Jr SC, Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovascular research. 2011; 90(2):194-201.

22. Levy D. Clinical significance of left ventricular hypertrophy: insights from the Framingham Study. Journal of cardiovascular pharmacology. 1991; 17:S1-6.

23. Heinzel FR, Hohendanner F, Jin G, Sedej S, Edelmann F. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. Journal of applied physiology. 2015; 119(10):1233-42.

24. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Annals of internal medicine. 1991; 114 (5):345-52.

25. López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. Journal of the American College of Cardiology. 2006; 48(1):89-96.

26. Alkema M, Spitzer E, Soliman OI, Loewe C. Multimodality imaging for left ventricular hypertrophy severity grading: a methodological review. Journal of cardiovascular ultrasound. 2016; 24(4):257-67.

27. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. Journal of nuclear cardiology. 2006; 13(1):24-33.

28. Chow BJ, Wong JW, Yoshinaga K, Ruddy TD, Williams K, DaSilva J, et al. Prognostic significance of dipyridamole-induced ST depression in patients with normal 82Rb PET myocardial perfusion imaging. Journal of Nuclear Medicine. 2005; 46(7):1095-101.